A phase II/III study of BHV-0223 for the treatment of spinocerebellar ataxia.

Trial Profile

A phase II/III study of BHV-0223 for the treatment of spinocerebellar ataxia.

Planning
Phase of Trial: Phase II/III

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Riluzole (Primary)
  • Indications Spinocerebellar ataxias
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2016 According to Biohaven Pharmaceutical media release, company plans to initiate Phase 2/3 studies in 4Q2016 and in 2017.
    • 11 Mar 2016 New trial record
    • 03 Mar 2016 According to a Biohaven media release, the company expects to initiate this trial of BHV-0223 for the treatment of spinocerebellar ataxia before the end of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top